title: Schedules of Controlled Substances: Placement of Brivaracetam Into Schedule V. Final rule.
abstract: This final rule adopts without change an interim final rule with request for comments published in the Federal Register on May 12, 2016. The Drug Enforcement Administration is placing the substance brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also referred to as BRV; UCB-34714; Briviact) (including its salts) into schedule V of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act, as revised by the Improving Regulatory Transparency for New Medical Therapies Act which was signed into law on November 25, 2015.
mesh_terms: D000927:Anticonvulsants / Q000145:classification; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D006801:Humans; D011760:Pyrrolidinones / Q000145:classification*; D014481:United States
chemical_list: D000927:Anticonvulsants; D011760:Pyrrolidinones